To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The cost-effectiveness of… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

The cost-effectiveness of biological therapy cycles in the management of Crohn's disease.

Journal article
Authors Kristian Bolin
Erik Hertervig
Edouard Louis
Published in Journal of Crohn's & colitis
Volume 13
Issue 10
Pages 1323–1333
ISSN 1876-4479
Publication year 2019
Published at Centre for Health Economics
Department of Economics
Pages 1323–1333
Language en
Subject categories Health Care Service and Management, Health Policy and Services and Health Economy


to examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn's disease in clinical remission, with a combination of anti-TNFα (infliximab) and immunomodulator therapy compared to two different withdrawal strategies (1) withdrawal of the anti-TNFα therapy, and (2) withdrawal of the immunomodulator therapy, respectively.A decision-tree model was constructed mimicking three treatment arms: (1) continued combination therapy with infliximab and immunomodulator, (2) withdrawal of infliximab, or (3) withdrawal of the immunomodulator. Relapses in each arm are managed with treatment intensification and reinstitution of the de-escalated drug according to a prespecified algorithm. State dependent relapse risks, remission probabilities and quality of life weights were collected from previous published studies.Combination therapy was less costly and more efficient than the withdrawal of the immunomodulator, and more costly and more efficient than withdrawal of infliximab. Whether or not combination therapy is cost effective, compared to the alternatives, depends, primarily, on current pharmaceutical prices and the willingness to pay per additional QALY.Combination therapy using a combination of anti-TNFα (infliximab) and an immunomodulator is cost effective in the treatment of Crohn's disease compared to treatment cycles in which the immunomodulator is withdrawn. Combination treatment is cost effective compared to treatment cycles in which infliximab is withdrawn, at prices of infliximab below € 192/100 mg, given a willingness-to-pay threshold at € 49 020 (Sweden) per additional QALY.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?